Fundz
An acquisition means integration work is about to be scoped. Fundz scores the company against what you sell, and says why it matched.See it live →

Impact Biomedical to merge with Zoar Limited

PRIVATESep 15, 2026about 2 hours ago

Acquiring Company

Zoar Limited

Acquired Company

Impact Biomedical

TexasBiotechnologyHealth CareBiotechnologyHealth Care

Description

Impact Biomedical Inc. has announced a merger with Zoar Limited, enabling stockholders to exchange shares at a 1:1 ratio post-reverse stock split. This merger focuses on enhancing pharmaceutical capabilities. The transaction, pending approval, aims to develop specialized therapeutic areas. A reverse stock split will precede the merger to consolidate shares.

Company Information

Company

Zoar Limited

About

Zoar Limited specializes in the development and supply of Active Pharmaceutical Ingredients and intermediates. The company focuses on special therapeutic treatment areas. This merger aims to expand its capabilities and offerings. It was previously known as Dr Ashleys Limited.

Don't miss Zoar Limited's next move

Get an email the moment Zoar Limited makes an acquisition, hires an exec, or expands, usually minutes after it happens.

One email per event. Unsubscribe anytime.

Predictive Intelligence
Strategic

ML-powered predictions for Zoar Limited's next move

Learn about Strategic plan

M&A Insights

Based on deal data
Integration timeline
70% of M&A integrations take 12-24 months to complete
Tech stack consolidation
83% of merged companies consolidate technology vendors within first year
Post-acquisition investment
Companies increase IT spending by 23% on average after acquisitions
Success factor
M&A deals with strong technology integration plans are 2.5x more likely to succeed

Frequently asked

Who acquired Impact Biomedical?

Impact Biomedical was acquired by Zoar Limited. The deal was reported on September 15, 2026. Zoar Limited specializes in the development and supply of Active Pharmaceutical Ingredients and intermediates. The company focuses on special therapeutic treatment areas. Zoar Limited is privately held and operates in Biotechnology.

When did Zoar Limited acquire Impact Biomedical?

Zoar Limited's acquisition of Impact Biomedical was reported on September 15, 2026. Impact Biomedical Inc. has announced a merger with Zoar Limited, enabling stockholders to exchange shares at a 1:1 ratio post-reverse stock split. This merger focuses on enhancing pharmaceutical capabilities. Fundz records the date the transaction was first publicly reported, sourced from filings and company announcements.

What does Impact Biomedical do?

Impact Biomedical Inc. is a biotechnology company specializing in the development of innovative healthcare solutions. It is publicly traded and focuses on advancing biopharmaceutical products. It is publicly traded (IBO), operating in Biotechnology, and is based in Texas.

This company was part of an acquisition. Fundz tracks who bought whom, and who to call on both sides.

145 of these a day, filtered to the companies you pick. $29 a month, billed annually, and if it does not pay for itself in a year we refund it.

5 screens from a live account. No signup.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include FundzWatch™ for automated website change detection, Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 285,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.